Amylyx Pharmaceuticals, Inc. (AMLX)
USD 3.94
(-7.94%)
USD 3.94
(-7.94%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 11.91 Million | -179.87 Million | -74.79 Million | -36.69 Million | -10.68 Million |
| Net Income | 49.27 Million | -198.37 Million | -87.93 Million | -42.28 Million | -13.71 Million |
| Depreciation & Amortization | 1.08 Million | 487 Thousand | 52 Thousand | 1000.00 | - |
| Deferred income taxes | - | - | 121 Thousand | 1 Million | - |
| Stock-based compensation | 37.16 Million | 21.71 Million | 3.13 Million | 243 Thousand | 108 Thousand |
| Change in working capital | -65.66 Million | -1.64 Million | 4.59 Million | 2.59 Million | 3.5 Million |
| Other non-cash items | -9.94 Million | -2.05 Million | 5.22 Million | 1.73 Million | -583 Thousand |
| Investing Cash Flow | 92.05 Million | -238.98 Million | -46.4 Million | -151 Thousand | - |
| Investments in PPE | -1.24 Million | -2.52 Million | -353 Thousand | -151 Thousand | - |
| Acquisitions | -92.05 Million | 236.46 Million | -3 Million | - | - |
| Investment purchases | -300.82 Million | -415.87 Million | -49.05 Million | - | - |
| Sales/Maturities of investments | 394.12 Million | 179.41 Million | 3 Million | - | - |
| Other Investing Activities | 92.05 Million | -236.46 Million | 3 Million | - | - |
| Financing Cash Flow | 3.54 Million | 431.78 Million | 158.5 Million | 46.82 Million | 668 Thousand |
| Debt repayment | - | - | -263 Thousand | -16.81 Million | -641 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -3.31 Million | - | - | - | - |
| Common Stock Issuance | 6.85 Million | 431.78 Million | 135 Million | 30 Million | 27 Thousand |
| Other Financing Activities | -3.31 Million | 431.78 Million | 23.76 Million | 33.63 Million | 1.28 Million |
| Accounts receivables | -24.74 Million | -15.3 Million | - | - | - |
| Accounts payables | 15.88 Million | 1.85 Million | 670 Thousand | 1.41 Million | 1.28 Million |
| Inventory | -73.12 Million | -9.76 Million | - | - | - |
| Other working capital | 16.33 Million | 21.58 Million | 3.92 Million | 1.18 Million | 2.22 Million |
| Cash at beginning of period | 63.24 Million | 50.38 Million | 13.06 Million | 3.09 Million | 13.11 Million |
| Cash at end of period | 170.92 Million | 63.24 Million | 50.38 Million | 13.06 Million | 3.09 Million |
| Capital Expenditure | -1.24 Million | -2.52 Million | -353 Thousand | -151 Thousand | - |
| Effect of forex changes on cash | 160 Thousand | -65 Thousand | 13 Thousand | - | - |
| Net cash flow / Change in cash | 107.67 Million | 12.86 Million | 37.31 Million | 9.97 Million | -10.01 Million |
| Free Cash Flow | 10.67 Million | -182.39 Million | -75.15 Million | -36.84 Million | -10.68 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -72.7 Million | -118.79 Million | 4.73 Million | 49.27 Million | 20.89 Million | 22.07 Million |
| Depreciation & Amortization | 208 Thousand | 315 Thousand | 301 Thousand | 1.08 Million | 302 Thousand | 281 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 9.57 Million | 9.92 Million | 9.53 Million | 37.16 Million | 10.17 Million | 9.95 Million |
| Change in working capital | -8.69 Million | 164 Thousand | 1.55 Million | -65.66 Million | -34.05 Million | -21.71 Million |
| Other non-cash items | 15.19 Million | 108.66 Million | -2.57 Million | -9.94 Million | -2.48 Million | -1.98 Million |
| Investing Cash Flow | -28.96 Million | 819 Thousand | 20.92 Million | 92.05 Million | -108.08 Million | 123.22 Million |
| Investments in PPE | -89 Thousand | -67 Thousand | -356 Thousand | -1.24 Million | -357 Thousand | -278 Thousand |
| Acquisitions | - | - | -21.28 Million | -92.05 Million | 107.73 Million | - |
| Investment purchases | -158.87 Million | -73.11 Million | -126.63 Million | -300.82 Million | -164.43 Million | - |
| Sales/Maturities of investments | 130 Million | 74 Million | 147.92 Million | 394.12 Million | 56.7 Million | 123.5 Million |
| Other Investing Activities | -28.87 Million | 886 Thousand | 21.28 Million | 92.05 Million | -107.73 Million | 123.5 Million |
| Financing Cash Flow | 27 Thousand | 131 Thousand | 230 Thousand | 3.54 Million | 889 Thousand | 1.38 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -20 Thousand | -1.31 Million | -117 Thousand | -3.31 Million | -95 Thousand | -740 Thousand |
| Common Stock Issuance | 47 Thousand | 1.44 Million | 347 Thousand | 6.85 Million | 984 Thousand | 2.12 Million |
| Other Financing Activities | -20 Thousand | -1.31 Million | -117 Thousand | -3.31 Million | -95 Thousand | -740 Thousand |
| Accounts receivables | 16.26 Million | 19.69 Million | -10.69 Million | -24.74 Million | 4.12 Million | -15.91 Million |
| Accounts payables | -16.43 Million | -652 Thousand | 15.82 Million | 15.88 Million | -18.39 Million | 13.84 Million |
| Inventory | - | -9.25 Million | -26.48 Million | -73.12 Million | -14.01 Million | -19.33 Million |
| Other working capital | -8.52 Million | -9.62 Million | 22.91 Million | 16.33 Million | -5.77 Million | -306 Thousand |
| Cash at beginning of period | 170.55 Million | 170.2 Million | 135.97 Million | 63.24 Million | 248.47 Million | 115.28 Million |
| Cash at end of period | 74.99 Million | 170.55 Million | 170.92 Million | 170.92 Million | 135.97 Million | 248.47 Million |
| Capital Expenditure | -89 Thousand | -67 Thousand | -356 Thousand | -1.24 Million | -357 Thousand | -278 Thousand |
| Effect of forex changes on cash | -39 Thousand | -110 Thousand | 237 Thousand | 160 Thousand | -134 Thousand | -18 Thousand |
| Net cash flow / Change in cash | -95.55 Million | 351 Thousand | 34.94 Million | 107.67 Million | -112.5 Million | 133.19 Million |
| Free Cash Flow | -66.66 Million | -556 Thousand | 13.19 Million | 10.67 Million | -5.52 Million | 8.33 Million |
5956
600202
7847
5759
AWR
1515